Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 8/20 | 0.40 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.38 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | DNPH1 | O43598 | 2/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.36 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.36 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22220010 | 0.89 | P2RY12 (0.42) | P2RY12P2RY2P2RY1P2RY6PRMT6 | |
| SCHEMBL5694197 | 0.89 | P2RY12 (0.42) | P2RY12P2RY2P2RY1P2RY6PRMT6 | |
| SCHEMBL5694261 | 0.88 | P2RY12 (0.42) | P2RY12P2RY2P2RY1P2RY6PRMT6 | |
| SCHEMBL5908151 | 0.85 | P2RY6 (0.42) | P2RY2P2RY6 | |
| SCHEMBL24321944 | 0.83 | P2RY12 (0.38) | P2RY12P2RY2P2RY1P2RY6PRMT6 | |
| SCHEMBL5694266 | 0.82 | P2RY12 (0.35) | P2RY12P2RY2P2RY1P2RY6PRMT6 | |
| SCHEMBL24323018 | 0.81 | P2RY12 (0.36) | P2RY12P2RY2P2RY1P2RY6PRMT6 | |
| SCHEMBL26109732 | 0.81 | PRMT6 (0.45) | P2RY12P2RY2P2RY1P2RY6PRMT6 | |
| SCHEMBL5694262 | 0.81 | P2RY12 (0.37) | P2RY12P2RY2P2RY1P2RY6DNPH1 | |
| SCHEMBL17066102 | 0.80 | P2RY12 (0.44) | P2RY12P2RY2P2RY1P2RY6PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1645561-A1 | METHOD OF SYNTHESIZING CYCLIC BISDINUCLEOSIDE | Mitsui Chemicals, Inc. (JP) | 2006-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | NSUN2, POLR2H, POLB | P2RY12 4312/4885P2RY2 3700/4885P2RY1 3789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.